ArticleThe Journal of clinical investigation1998
Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation.
Article in The Journal of clinical investigation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.
- The labeled-leukocyte scan in the study of abdominal abscesses.Molecular imaging and biology · 2010Pooled it
- Α-defensin expression of inflammatory response in open and laparoscopic colectomy for colorectal cancer.World journal of surgery · 2011Trial
- 2-chlorofatty acid modification of neutrophil proteins: identification, localization and role in NETosis.Cell communication and signaling : CCS · 2025Article
- Alpha-defensins increase NTHi binding but not engulfment by the macrophages enhancing airway inflammation in Alpha-1 antitrypsin deficiency.Frontiers in immunology · 2025Article
- Article
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Recombinant HNP-1 Produced by Escherichia coli Triggers Bacterial Apoptosis and Exhibits Antibacterial Activity against Drug-Resistant Bacteria.Microbiology spectrum · 2022Article
- Role of neutrophils in type 2 diabetes and associated atherosclerosis.The international journal of biochemistry & cell biology · 2021Review
- Neutrophil-derived granule cargoes: paving the way for tumor growth and progression.Cancer metastasis reviews · 2021Review
- Pathogen-Specific Bacterial Imaging in Nuclear Medicine.Seminars in nuclear medicine · 2018Review
- Human neutrophil peptide-1 promotes alcohol-induced hepatic fibrosis and hepatocyte apoptosis.PloS one · 2017Article
- Low concentrations of human neutrophil peptide ameliorate experimental murine colitis.International journal of molecular medicine · 2016Article
- Dying blood mononuclear cell secretome exerts antimicrobial activity.European journal of clinical investigation · 2016Article
- In vitro studies on the antimicrobial peptide human beta-defensin 9 (HBD9): signalling pathways and pathogen-related response (an American Ophthalmological Society thesis).Transactions of the American Ophthalmological Society · 2014Article
- Immune modulation by multifaceted cationic host defense (antimicrobial) peptides.Nature chemical biology · 2013Review
- Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2013Article
- Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate.PLoS neglected tropical diseases · 2013Article
- Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells.Mediators of inflammation · 2012Review
- Antimicrobial peptides as infection imaging agents: better than radiolabeled antibiotics.International journal of peptides · 2012Article
- The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides.Infection and immunity · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophil defensins (or human neutrophil peptides-HNP) are major constituents of the azurophilic granules of human neutrophils and have been shown to display broad-spectrum antimicrobial activity. Other activities of these defensins, which are released from stimulated neutrophils, include cytotoxic, stimulatory, and chemotactic activities toward a variety of target cells. We studied the potential use of HNP-1 for antibacterial therapy of experimental bacterial infections in mice. In experimental peritoneal Klebsiella pneumoniae infections in mice, HNP-1 injection was shown to markedly reduce bacterial numbers in the infected peritoneal cavity 24 h after infection. This antibacterial effect was found to be associated with an increased influx of macrophages, granulocytes, and lymphocytes into the peritoneal cavity. These leukocytes appeared to be a requirement for the antibacterial effect, since in leukocytopenic mice administration of HNP-1 did not display antibacterial activity. HNP-1 treatment also reduced bacterial numbers in experimental K. pneumoniae or Staphylococcus aureus thigh muscle infections. In this model, radiolabeled HNP-1 was found to accumulate at the site of infection, whereas most of the injected HNP-1 was rapidly removed from the circulation via renal excretion. These results demonstrate that neutrophil defensins display marked in vivo antibacterial activity in experimental infections in mice and that this activity appears to be mediated, at least in part, by local leukocyte accumulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.